CRL

Business profile & competitive position

Charles River Laboratories International, Inc. (CRL) sits in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. In practice, the company operates as a full-service, non-clinical drug-development partner. Its clients use CRL for research-model technologies, discovery and safety-assessment services (both GLP and non-GLP), and manufacturing-support products. The business is organized into three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, these segments contributed 21.1%, 59.8%, and 19.1% of the company’s $4.0 billion total revenue, respectively.

The competitive narrative is mixed. The company’s revenue footprint—more than 120 sites across more than 20 countries—and its end-to-end non-clinical offering give it scale and integration advantages. However, its current profitability metrics are negative: a net margin of -6.0% and an ROE of -7.7%. Those figures do not support a claim of a strong current margin moat. Instead, they show a business that is structurally important to pharmaceutical and biotech R&D but is still working through cost structures and demand cycles. Any competitive position argument rests more on breadth of service and global reach than on current returns to shareholders.

Financial posture

CRL’s market capitalization is $13.9 billion, with the stock recently trading at $288.5. The P/E ratio stands at -59.6, which is not a valuation premium; it reflects trailing losses. A negative net margin of -6.0% and a negative ROE of -7.7% confirm that earnings power is currently below the cost of equity, so traditional earnings-based valuation cannot be read in the usual way. The current price is roughly 12.2% above the 50-day EMA of $257.03, and the RSI is 60.1, suggestive of near-term momentum without being technically overbought.

With $4.0 billion in 2025 revenue, the market is valuing the company at about 3.5x trailing sales. That multiple tells investors they are paying for a turnaround in margin rather than for current profit. The beta is 1.41, meaning the stock has moved roughly 41% more than the broader market historically, so any macro or earnings surprise tends to be amplified. The financial posture, therefore, is one of a recovery story: revenue scale is intact, but the market requires evidence that margins can move into positive territory and stay there.

Strategic priorities & outlook

Charles River’s most recent 10-K outlines a near-term operational agenda centered on footprint optimization, organizational integration, and biologics expansion. The company plans to close or consolidate approximately 12 additional sites over the next two years, principally within DSA and RMS. The stated goal of this consolidation is to streamline the global footprint and remove cost from the network.

At the same time, management is integrating Discovery Services and Safety Assessment into a single DSA organization with a combined sales force and unified leadership structure. The intent is to present one integrated non-clinical offering to clients rather than having customers negotiate separate discovery and safety workstreams. On the growth side, CRL says it will continue expanding Biologics Testing Solutions service offerings and facilities in the U.S. and Europe, a segment aligned with biologics and cell-and-gene therapy pipelines.

Finally, in January 2026 the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. That acquisition points to a strategic emphasis on securing research-model supply, especially primates, which are a constrained and regulated input for safety assessment.

Macro & geopolitical exposure

As a Healthcare / Medical – Diagnostics & Research company, CRL is exposed to several macro and geopolitical forces common to contract research and manufacturing organizations. Regulatory risk is central: FDA, EMA, and other national regulators enforce strict GLP and GMP standards, and any tightening of safety, data-integrity, or animal-welfare rules can raise compliance costs. Because the company relies on research animals, including non-human primates, it is also exposed to animal-rights activism, import/export restrictions, and biosafety regulations that can suddenly limit supply or increase public scrutiny.

Currency exposure matters because over 120 sites are spread across more than 20 countries, meaning revenue and costs are denominated in euros, pounds, yen, and other currencies in addition to the U.S. dollar. Trade policy is another factor: cross-border shipments of biologics, reagents, and research models can be disrupted by tariffs, customs delays, or sanctions. Finally, CRL is tied to pharmaceutical and biotechnology R&D budgets, which themselves are sensitive to interest rates, capital-market funding conditions, and the pace of new drug development.

Recent developments

The most recent headline flow has been dominated by post-earnings price action. On September 4, 2026, Zacks published a note observing that CRL had risen 10.5% since its last earnings report. That move is consistent with the August 5, 2026 quarterly release, when the stock gained 1.84% the next day and 9.07% over the following five trading days. On September 1, 2026, another Zacks piece asked whether it was the “right time” to add CRL stock, a question that ties back to the same post-earnings momentum and valuation crosscurrents. On August 31, 2026, defenseworld.net ran a comparison between Charles River Laboratories and IB Acquisition, and on August 27, 2026, fool.com covered congressional momentum behind the Clarity Act—the latter not a CRL-specific item, but a reminder that regulatory and policy headlines can ripple through healthcare and life-science sentiment.

Earnings behavior & post-earnings drift

CRL’s earnings track record is mechanically strong. Over the last eight reported quarters, the company has beaten earnings estimates 8 out of 8 times, a 100% beat rate, with an average earnings surprise of 9.3%. The average 5-day post-earnings drift across those quarters has been +1.24%, classified as “up.”

Drilling into the four most recent quarters shows that beats do not always translate into immediate upward moves. The May 7, 2026 report delivered EPS of $2.06 versus a $1.96 estimate, a 5.1% surprise, yet the stock fell 2.23% the next day and was down 12.42% over the next five sessions. By contrast, the August 5, 2026 report showed EPS of $3.02 against a $2.74 estimate, a 10.2% surprise, with the stock rising 1.84% the next day and 9.07% over the following five days. Earlier prints: November 5, 2025 ($2.43 vs. $2.32, 4.7% surprise) produced a 1.9% next-day gain and a 2.27% five-day gain; February 18, 2026 ($2.39 vs. $2.33, 2.6% surprise) produced a 3.95% next-day gain and a 6.05% five-day gain.

The next scheduled report is November 4, 2026, before the market open, with an unofficial consensus EPS estimate of $2.96. Because the 100% beat streak is already widely known, the market has likely priced in a strong number to some degree; the reaction may depend more on guidance, margins, and segment commentary than on whether the company beats by a few cents.

For a deeper dive into how institutional analysts are interpreting CRL’s margin trajectory, strategic site consolidation, and upcoming November 4, 2026 earnings report, review the full institutional verdict on the platform.